SUBSCRIPTION AGREEMENTSubscription Agreement • February 14th, 2017 • Quotient LTD • In vitro & in vivo diagnostic substances • New York
This Subscription Agreement (“Agreement”), dated as of February 9, 2017, sets forth the terms and conditions upon which Quotient Limited, a company organized under the laws of Jersey (the “Company”), will issue, and Christopher J. Lindop (the “Subscriber”) will subscribe for, an aggregate of 50,000 ordinary shares (the “Shares”), of no par value per share, of the Company (for cash at a price of $6.41 per Share (the “Subscription Price”). The Subscription Price per Share is equal to the closing sales price of the Company’s ordinary shares as reported on the Nasdaq Global Market on the date of this Agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • February 14th, 2017 • Quotient LTD • In vitro & in vivo diagnostic substances • Delaware
This Employment Agreement (“Employment Agreement”) is entered into as of February 9, 2017 (the “Effective Date”), by and between Quotient Limited (“Employer”), or such affiliate of Employer as its Chairman of the Board of Directors of the Employer (the “Board”) may designate, and Christopher Lindop (“Executive”) (collectively, the “Parties”).
